Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations.

The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.Drugs (Pharmaceuticals), Aduhelm (Drug), Alzheimer’s Disease, Medicare, Biogen Inc, Cleveland Clinic, Blue Cross and Blue Shield Assn, Food and Drug Administration, Mount Sinai Medical Center, Veterans Affairs Department, Vounatsos, MichelRead More